Senescence β-Galactosidase Staining Kit #9860
Product Information
Protocol
Product Description
Background
Limited capacity to replicate is a defining characteristic of most normal cells and culminates in senescence, an arrested state in which the cell remains viable (1). Senescent cells are not stimulated to divide by serum or passage in culture, and senescence invokes a specific cell cycle profile that differs from most damage-induced arrest processes or contact inhibition (2). An enlarged cell size, expression of pH-dependent β-galactosidase activity (3), and an altered pattern of gene expression (4,5) further characterize senescent cells.
- Goldstein, S. (1990) Science 249, 1129-33.
- Sherwood, S. W. et al. (1988) Proc. Natl. Acad. Sci., USA 85, 9086-90.
- Dimri, G. et al. (1995) Proc. Natl. Acad. Sci., USA 92, 9363-7.
- Cristofalo, V. J. et al. (1998) Crit. Rev. Eukaryot Gene Expr. 8, 43-80.
- Linskens, M. H. et al. (1995) Nucleic Acid Res. 23, 3244-51.
Product Citations: 63
- Baker, D. J. et al. (2004) Nat. Genetics 36, 744-749.
- Su, D. et al. (2009) J Biol Chem 284, 12153-64.
- Swarbrick, A. et al. (2008) Proc Natl Acad Sci U S A 105, 5402-7.
- Efeyan, A. et al. (2007) Cancer Res 67, 7350-7.
- Boucher, M.J. et al. (2004) Am J Physiol Gastrointest Liver Physiol 286, G736-46.
- Efeyan, A. et al. (2009) PLoS One 4, e5475.
- Chang, C.J. et al. (2011) Nat Cell Biol 13, 317-23.
- Delmore, J.E. et al. (2011) Cell 146, 904-17.
- Blasco, R.B. et al. (2011) Cancer Cell 19, 652-63.
- Cronin, J.C. et al. (2013) Cancer Res 73, 5709-18.
- Pérez de Castro, I. et al. (2013) Cancer Res 73, 6804-15.
- Wang, M. et al. (2014) Cancer Res 74, 2825-34.
- Park, E. et al. (2013) Mol Cell 50, 908-18.
- Rader, J. et al. (2013) Clin Cancer Res 19, 6173-82.
- Guo, J.Y. et al. (2013) Genes Dev 27, 1447-61.
- Evangelou, K. et al. (2013) Cell Death Differ 20, 1485-97.
- Khongkow, P. et al. (2014) Oncogene 33, 4144-55.
- Flach, J. et al. (2014) Nature 512, 198-202.
- Tang, Y. et al. (2013) Oncogene 32, 2792-8.
- Agrelo, R. et al. (2013) Oncogene 32, 5492-500.
- Li, Z. et al. (2013) Oncotarget 4, 2532-49.
- Gagou, M.E. et al. (2014) Oncotarget 5, 11381-98.
- Zhou, Z.W. et al. (2013) PLoS Genet 9, e1003702.
- Sanchez, N. et al. (2013) PLoS One 8, e65671.
- Li, L.H. et al. (2014) PLoS One 9, e104203.
- Arason, A.J. et al. (2014) PLoS One 9, e88683.
- Krencik, R. et al. (2015) Sci Transl Med 7, 286ra66.
- Kovatcheva, M. et al. (2015) Oncotarget 6, 8226-43.
- Chen, R. et al. (2015) Oncotarget 6, 32841-55.
- Kannan, A. et al. (2016) Oncotarget 7, 6576-92.
- Havel, J.J. et al. (2015) Oncogene 34, 1487-98.
- Defamie, V. et al. (2015) Oncogene 34, 4098-108.
- Khongkow, P. et al. (2016) Oncogene 35, 990-1002.
- Castillo-Lluva, S. et al. (2015) Oncogene 34, 4777-90.
- Wan, Y. et al. (2015) J Cell Biol 209, 235-46.
- Yuan, Y. et al. (2016) J Biol Chem 291, 1307-19.
- Gabitova, L. et al. (2015) Cell Rep 12, 1927-38.
- Solovjeva, L. et al. (2015) BMC Mol Biol 16, 18.
- Chung, S.I. et al. (2016) Oncotarget 7, 7354-66.
- Lowe, D. et al. (2016) Oncotarget 7, 8524-31.
- Lee, H. et al. (2016) Oncotarget 7, 19134-46.
- Chang, J. et al. (2016) Nat Med 22, 78-83.
- Baker, D.J. et al. (2016) Nature 530, 184-9.
- Takai, H. et al. (2016) Genes Dev 30, 812-26.
- Borghesan, M. et al. (2016) Cancer Res 76, 594-606.
- De Amicis, F. et al. (2016) Oncotarget , 57955-57969.
- Oh, A.Y. et al. (2016) Cancer Res 76, 4791-804.
- Lawson, C.D. et al. (2016) Cancer Res 76, 3826-37.
- Liceras-Boillos, P. et al. (2016) Oncogene , .
- Sriraman, A. et al. (2016) Oncotarget 7, 31623-38.
- Lee, H. et al. (2016) Oncotarget 7, 19134-46.
- Lowe, D. et al. (2016) Oncotarget 7, 8524-31.
- Borghesan, M. et al. (2016) Cancer Res 76, 594-606.
- Yuan, Y. et al. (2016) J Biol Chem 291, 1307-19.
- Kannan, A. et al. (2016) Oncotarget 7, 6576-92.
- Shao, Z. et al. (2016) Nat Commun 7, 10869.
- Xiong, Z.M. et al. (2016) Aging Cell 15, 279-90.
- Soriano-Arroquia, A. et al. (2016) Aging Cell 15, 361-9.
- Llanos, S. et al. (2016) Nat Commun 7, 10438.
- Walter, D. et al. (2016) Nat Commun 7, 10530.
- Felsenstein, K.M. et al. (2016) ACS Chem Biol 11, 139-48.
- Frame, F.M. et al. (2016) Cancer Med 5, 61-73.
- Zhu, N. et al. (2016) Stem Cells Int 2016, 5687589.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.